Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c
August 9, 2016 7:55 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33).
2016 Financial Guidance
Cash, cash equivalents, and marketable securities totaled $214.2 million at June 30, 2016. The Companys balance sheet was strengthened during the second quarter of 2016 with $57.8 million in net proceeds under the... More
